Meta-analysis of randomized trials: SGLT-2 inhibitors and GLP-1 receptor agonists reduce cardiovascular and renal outcomes in type 2 diabetes
15 Jan, 2021 | 08:41h | UTCCalculator based on the results: interactive decision support tool for outcomes
Calculator based on the results: interactive decision support tool for outcomes